NRP2 and breast cancer: We then showed that an antibody against Nrp2 reduces cytoplasmic CXCR4 expression and inhibited CXCL12-induced chemotaxis in MDA-MB-231 breast cancer cells, which were previously shown to express endogenous Nrp2 [8].